

## NOVEMBER

Date	Headline and Source	Link	Summary
3 <sup>rd</sup> November	Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians Business News This Week, November 03, 2024	<a href="#">Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians</a>	Hyderabad, 02nd November 2024: Bayer's Consumer Health Division proudly introduces Bepanthen, the world's leading skincare brand, to the Indian market along with a survey conducted by Ipsos among Indian dermatologists, emphasizing the high occurrence of dry skin among general population.
3 <sup>rd</sup> November	PM Modi unveils Ayushman Vaya Vandana Card, free healthcare for all seniors above 70 DD News, November 03, 2024	<a href="#">PM Modi unveils Ayushman Vaya Vandana Card, free healthcare for all seniors above 70</a>	In a significant step, Prime Minister Narendra Modi has launched the Ayushman Vaya Vandana Card under the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB PM-JAY). This expanded scheme offers free health coverage of up to 5 lakh annually for every citizen aged 70 years and above, irrespective of income or economic status.
4 <sup>th</sup> November	Big pharma rides the GCC wave The Financial Express, November 04, 2024	<a href="#">Big pharma rides the GCC wave</a>	Pharmaceutical industry makes up 6% of the GCC footprint with about 38 GCCs that employ around 80,000 people. In the context of the pharma sector, it's safe to say that India is no longer just the pharmacy of the world; it is rapidly emerging as a hub of pharma innovation, feels Anil Matai, director general, Organisation of Pharmaceutical Producers of India (OPPI).
4 <sup>th</sup> November	Sanofi Healthcare Gets CDSCO Panel Nod to Study Asthma Drug SAR443765 Medical Dialogues, November 04, 2024	<a href="#">Sanofi Healthcare Gets CDSCO Panel Nod to Study Asthma Drug SAR443765</a>	New Delhi: The drug major Sanofi Healthcare has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation CDSCO to conduct the trial of the pulmonary drug SAR443765 (unseizing) solution for injection 165 mg/1.1 mL (150 mg/mL).
5 <sup>th</sup> November	CDSCO Panel Approves Pfizer Protocol Amendment proposal to study anticancer drug Elranatamab Medical Dialogues, November 05, 2024	<a href="#">CDSCO Panel Approves Pfizer Protocol Amendment proposal to study anticancer drug Elranatamab</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Pfizer's protocol amendment proposal for the clinical trial titled A Phase 3 Study with Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant.
6 <sup>th</sup> November	PLI & Ayushman Bharat initiatives will transform		The Director General of the Organization of Pharmaceutical Producers of India (OPPI)

	Indian pharma & healthcare sectors: Anil Matai PharmaBiz, November 06, 2024	<a href="#">PLI &amp; Ayushman Bharat initiatives will transform Indian pharma &amp; healthcare sectors: Anil Matai</a>	Anil Matai is of the view that the production-linked incentive (PLI) scheme and the Ayushman Bharat initiative will prove to be pivotal for transforming the Indian pharmaceutical and healthcare sectors respectively.
6 <sup>th</sup> November	Government of Goa and Novo Nordisk India flagoff Tour De Diabetes to raise awareness ahead of World Diabetes Day Goemkarponn, November 06, 2024	<a href="#">Government of Goa and Novo Nordisk India flagoff Tour De Diabetes to raise awareness ahead of World Diabetes Day</a>	Ahead of World Diabetes Day, Directorate of Health Services, Government of Goa, Novo Nordisk India Private Limited and Novo Nordisk Global Business Services flagged off Tour de Diabetes a fourcity tour aimed at raising awareness about diabetes and promoting wellbeing across India.
7 <sup>th</sup> November	Novo Nordisk expects high demand for its obesity drugs in India, says country head The Print, November 07, 2024	<a href="#">Novo Nordisk expects high demand for its obesity drugs in India, says country head</a>	Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when launched in India, a top executive said. Government intervention is necessary to raise awareness among the larger Indian population about obesity being a chronic disease, Shrotriya said on Wednesday, while presenting a 2022 Novofunded study on India's obesity market.
8 <sup>th</sup> November	CDSCO panel Approves AstraZeneca's Protocol Amendment proposal for Datopotamab Deruxtecan study Medical Dialogues, November 08, 2024	<a href="#">CDSCO panel Approves AstraZeneca's Protocol Amendment proposal for Datopotamab Deruxtecan study</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved AstraZeneca s protocol amendment proposal to study anticancer drug Datopotamab Deruxtecan (DATODXT, DS106) This came after the firm presented protocol amendment 3.0 version 4.0 dated 30 July 2024, protocol no. D926PC00001.
10 <sup>th</sup> November	Pfizer Gets CDSCO Panel Nod To Conduct Phase III CT of Rimegepant Medical Dialogues, November 10, 2024	<a href="#">Pfizer Gets CDSCO Panel Nod To Conduct Phase III CT of Rimegepant</a>	Pharmaceutical major Pfizer has received the goahead from the Subject Expert Committee (SEC), which is functional under the Central Drug Standard Control Organisation (CDSCO), to conduct the Phase III clinical study of the calcitonin generelated peptide receptor antagonist Rimegepant.
12 <sup>th</sup> November	Pfizer to fund six startups through its INDOvation program for healthcare The Economic Times, November 12, 2024	<a href="#">Pfizer to fund six startups through its INDOvation program for healthcare</a>	Pfizer in collaboration with National Institute of Pharmaceutical Education & Research (NIPER)-Ahmedabad, the Department of Pharmaceuticals (DoP), NITI Aayog and Social Alpha, on Monday announced six winners of the NIPER-A edition of Pfizer's flagship INDOvation program for healthcare start-ups.

12 <sup>th</sup> November	Almost 70 pc of what we sell in India, we Make in India : Pfizer MD Meenakshi Nevatia ANI News, November 12, 2024	<a href="#">Almost 70 pc of what we sell in India, we Make in India : Pfizer MD Meenakshi Nevatia</a>	Pfizer Limited's Managing Director, Meenakshi Nevatia, has reaffirmed the company's dedication to India, highlighting its extensive Make in India initiatives. She emphasised that almost 70% of Pfizer's products sold in India are manufactured domestically, either through its own plant in Goa or via 18 contract partners.
13 <sup>th</sup> November	GSK is celebrating its 100 years of presence in India LinkedIn, November 13, 2024	<a href="#">GSK is celebrating its 100 years of presence in India</a>	A truly remarkable organization, from a quarter of those historic years that I followed as a journalist. GSK's market share has slipped to rank #14, shows the latest PharmaTrac data but in its glorious years, it was always a neck-and-neck race with Cipla and Ranbaxy for the top slot. That success pointed to GSK's core thinking for the Indian patients.
13 <sup>th</sup> November	Pfizer to fund six startups through INDovation program for healthcare Entracker, November 13, 2024	<a href="#">Pfizer to fund six startups through INDovation program for healthcare</a>	In collaboration with the National Institute of Pharmaceutical Education & Research (NIPER)Ahmedabad, the Department of Pharmaceuticals (DoP), NITI Aayog, and Social Alpha, Pfizer has announced six winners of the NIPERA edition of its flagship INDovation program for healthcare startups.
13 <sup>th</sup> November	Pfizer to expand manufacturing and R&D capacities; Company aims to launch more Made-in-India products The Financial Express, November 13, 2024	<a href="#">Pfizer to expand manufacturing and R&amp;D capacities; Company aims to launch more Made-in-India products</a>	Meenakshi Nevatia, Managing Director of Pfizer Limited on Tuesday said that the company is planning to expand its manufacturing capacity and it is focusing on research and development. Nevatia also revealed that the pharma major is aiming to bring more made in India products in the market.
14 <sup>th</sup> November	India's import dependence on key pharma ingredients may reduce by half Business Standard, November 14, 2024	<a href="#">India's import dependence on key pharma ingredients may reduce by half</a>	Anil Matai, director general Organisation of Pharmaceutical Producers of India (OPPI), stated that Penicillin G and Clavulanic Acid have historically been sourced primarily from China, leaving the Indian pharmaceutical sector vulnerable to external supply disruptions.
14 <sup>th</sup> November	Pfizer to expand manufacturing and R&D capacities: MD The Economic Times, November 14, 2024	<a href="#">Pfizer to expand manufacturing and R&amp;D capacities: MD</a>	Pfizer to expand manufacturing and R&D capacities: MD Speaking with Nevatia said that the company is aiming to bring more made in India products in the market. The company is in the middle of shifting its oncology, and chemotherapy, products from Australia to Gujarat.
14 <sup>th</sup> November	Sanofi Gets CDSCO Panel Nod to Study Venglustat	<a href="#">Sanofi Gets CDSCO Panel Nod to Study Venglustat</a>	Reviewing the Phase III clinical trial protocol of the GZ402671 (Venglustat) presented by the pharma major Sanofi, the

	Medical Dialogues, November 14, 2024		Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted permission to conduct the trial as presented by the firm.
15 <sup>th</sup> November	GSK Celebrates Hundred Years in India Chemin Digest, November 15, 2024	<a href="#">GSK Celebrates Hundred Years in India</a>	British biopharmaceutical firm GlaxoSmithKline (GSK) marked a significant milestone, completing hundred years of operations in India. The journey of GSK in India has been marked by groundbreaking innovations, from producing the antibiotic penicillin to developing Augmentin and pioneering pediatric vaccines.
15 <sup>th</sup> November	50 children to get lifelong access to free Roche drug for SMA treatment BioSpectrum India, November 15, 2024	<a href="#">50 children to get lifelong access to free Roche drug for SMA treatment</a>	Care and Protection of Children Trust signs agreement with Roche Pharma India to procure Risdiplam Tamil Nadu-based Care and Protection of Children Trust (CPCT), a leading NGO committed to alleviating the burden of rare diseases, has announced the launch of a groundbreaking financial assistance initiative aimed at supporting children diagnosed with Spinal Muscular Atrophy (SMA).
15 <sup>th</sup> November	AstraZeneca India partners with IAP to raise awareness on RSV in India The Financial Express, November 15, 2024	<a href="#">AstraZeneca India partners with IAP to raise awareness on RSV in India</a>	AstraZeneca Pharma India Ltd on Thursday announced a strategic collaboration with the Indian Academy of Paediatrics to raise awareness on Respiratory Syncytial Virus (RSV) that can put newborn preterm babies at risk of respiratory illnesses and the need for timely intervention thereof.
18 <sup>th</sup> November	Sightsavers India and AbbVie Partner for 4th State-Level Consultation on Glaucoma Prevention Business News This Week, November 18, 2024	<a href="#">Sightsavers India and AbbVie Partner for 4th State-Level Consultation on Glaucoma Prevention</a>	Sightsavers India and AbbVie India, in their ongoing collaborative campaign, recently hosted the fourth state-level consultation on the 'Prevention of Visual Impairment Caused by Glaucoma' at the NIMHANS Convention Centre in Bengaluru, Karnataka.
19 <sup>th</sup> November	AstraZeneca to launch Breztri Aerosphere for COPD treatment following DCGI approval The Economic Times, November 19, 2024	<a href="#">AstraZeneca to launch Breztri Aerosphere for COPD treatment following DCGI approval</a>	AstraZeneca to launch Breztri Aerosphere for COPD treatment following DCGI approval AstraZeneca Pharma India has received DCGI approval to import and market Breztri Aerosphere, an inhalation therapy for COPD treatment. The product, combining three active ingredients, is set to launch in India in January 2025.
19 <sup>th</sup> November	Sightsavers India, AbbVie India launch campaign to prevent visual impairment	<a href="#">Sightsavers India, AbbVie India launch campaign to prevent</a>	At the consultation, distinguished guests, including health officials and advocates for eye health, highlighted the importance

	from Glaucoma Healthcare Radius, November 19, 2024	<a href="#">visual impairment from Glaucoma</a>	of collaborative efforts to enhance eye care services. Sightsavers India and AbbVie India, in their ongoing collaborative campaign, recently hosted the fourth state-level consultation on the Prevention of Visual Impairment Caused by Glaucoma at the NIMHANS Convention Centre in Bengaluru, Karnataka.
20 <sup>th</sup> November	Merck Life Science inks MoU with Genext Genomics BioSpectrum India, November 20, 2024	<a href="#">Merck Life Science inks MoU with Genext Genomics</a>	Merck Life Science in India has signed a Memorandum of Understanding (MoU) with GeNext Genomics, an emerging biotech company. The MoU was signed between Aditya Sharma, Head of Process Solutions, India Region, Merck Life Science; Dr Ashwin Kashikar, Managing Director, Genext Genomics; Supriya Kashikar, Founder & CEO, GeNext Genomics and Ravi Kashikar, Chairman and Founder of Ankur Seeds.
20 <sup>th</sup> November	RED.Health inks pact with Boehringer India arm to improve its stroke care services ET Health World, November 20, 2024	<a href="#">RED.Health inks pact with Boehringer India arm to improve its stroke care services</a>	RED.Health, an ambulance service provider signed a Memorandum of Understanding (MoU) with German drug maker Boehringer Ingelheim India arm under its angels initiative to strengthen its emergency prehospital stroke care services in India.
21 <sup>st</sup> November	Boehringer Ingelheim India, Red.Health to strengthen emergency prehospital stroke care in India Healthcare Radius, November 21, 2024	<a href="#">Boehringer Ingelheim India, Red.Health to strengthen emergency prehospital stroke care in India</a>	Boehringer Ingelheim India, through its Angels Initiative, signed a memorandum of understanding (MoU) with Red Health, the emergency care expert, will strengthen emergency prehospital stroke care services in India is currently witnessing a rise in stroke cases, and according to data, stroke is now the fourth leading cause of death and the fifth leading cause of disability.
21 <sup>st</sup> November	Merck Life Science inks MoU with Genext Genomics BioSpectrum India, November 21, 2024	<a href="#">Merck Life Science inks MoU with Genext Genomics</a>	Merck Life Science in India has signed a Memorandum of Understanding (MoU) with GeNext Genomics, an emerging biotech company. The MoU was signed between Aditya Sharma, Head of Process Solutions, India Region, Merck Life Science; Dr Ashwin Kashikar, Managing Director, Genext Genomics; Supriya Kashikar, Founder & CEO, GeNext Genomics and Ravi Kashikar, Chairman and Founder of Ankur Seeds.
21 <sup>st</sup> November	Merck's Injectable Keytruda Proves Effective in Trial, Promises Easier Cancer Treatment	<a href="#">Merck's Injectable Keytruda Proves Effective in Trial, Promises Easier Cancer Treatment</a>	Merck said on Tuesday a study showed that its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of its

	Medical Dialogues, November 21, 2024		treatment, likely making it even more accessible and easier to administer.
25 <sup>th</sup> November	Novartis Healthcare gets CDSCO Panel nod to study Iptacopan Medical Dialogues, November 25, 2024	<a href="#">Novartis Healthcare gets CDSCO Panel nod to study Iptacopan</a>	The drug major Novartis Healthcare has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the extension part of the study to evaluate the long-term efficacy, safety, and tolerability of iptacopan (LNP023) in C3 glomerulopathy or idiopathic immune complex membranoproliferative glomerulonephritis.
25 <sup>th</sup> November	FE Exclusive   India is a priority market; We aim to launch tirzepatide for obesity in India by 2025: Prof Rachel Batterham, Senior VP, International Medical Affairs, Eli Lilly The Financial Express, November 25, 2024	<a href="#">FE Exclusive   India is a priority market; We aim to launch tirzepatide for obesity in India by 2025: Prof Rachel Batterham, Senior VP, International Medical Affairs, Eli Lilly</a>	In the current obesity drug market, GLP1 agonists manufactured by Novo Nordisk and Eli Lilly have attracted the majority of the attention. Currently, the two companies hold a combined 68 percent of sales from weight-loss drugs, however, new entrants are set to challenge their market share, according to a report by Morningstar.
26 <sup>th</sup> November	Merck Life Science in India, GeNext Genomics sign MoU Express Pharma, November 26, 2024	<a href="#">Merck Life Science in India, GeNext Genomics sign MoU</a>	Merck Life Science in India signed a Memorandum of Understanding (MoU) with GeNext Genomics, an emerging biotech company. This collaboration aims to combine local expertise with global biomanufacturing capabilities.
27 <sup>th</sup> November	Merck Life Science in India inks MoU with Department for Promotion of Industry and Internal Trade BioSpectrum India, November 27, 2024	<a href="#">Merck Life Science in India inks MoU with Department for Promotion of Industry and Internal Trade</a>	Merck Life Science in India has signed a Memorandum of Understanding (MoU) with the Department for Promotion of Industry and Internal Trade (DPIIT) towards a Viksit Bharat. Sumeet Jarangal, Director, Startup India, DPIIT, and Aditya Sharma, Head of Process Solutions, India Region, Merck Life Science signed the MoU in the presence of Sanjiv Singh, Joint Secretary of DPIIT and other esteemed dignitaries from Startup India and DPIIT.
27 <sup>th</sup> November	AstraZeneca gets CDSCO nod to import cancer drug, Lynparza Business Standard, November 27, 2024	<a href="#">AstraZeneca gets CDSCO nod to import cancer drug, Lynparza</a>	AstraZeneca Pharma India said that it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Olaparib filmcoated tablets 100 mg & 150 mg (Lynparza) for an additional indication in India.
27 <sup>th</sup> November	Boehringer Ingelheim launches new poultry vaccine in India	<a href="#">Boehringer Ingelheim launches new poultry vaccine in India</a>	Boehringer Ingelheim announced the launch of the latest advancement in Marek s disease vaccines in India. This next generation vaccine offers enhanced



	The Hindu Business Line, November 27, 2024		protection through an innovative controlled attenuation process, delivering the right balance between safety and efficacy, the company said in a statement.
28 <sup>th</sup> November	Johnson & Johnson unveils India Detects to Defeat initiative to urge for early lung cancer detection and testing PharmaBiz, November 28, 2024	<a href="#">Johnson &amp; Johnson unveils India Detects to Defeat initiative to urge for early lung cancer detection and testing</a>	Johnson & Johnson (J&J) India announced the launch of its nationwide campaign, India Detects to Defeat, highlighting the critical role of early detection and testing in improving lung cancer outcomes. The first phase of this initiative features a collaboration with Amar Chitra Katha, one of India's most beloved storytellers, to create an engaging, illustrated booklet that simplifies complex medical information.
28 <sup>th</sup> November	Merck, DPIIT sign MoU to promote a manufacturing ecosystem The Times of India, November 28, 2024	<a href="#">Merck, DPIIT sign MoU to promote a manufacturing ecosystem</a>	Merck Life Science signed a Memorandum of Understanding (MoU) with the Department for Promotion of Industry and Internal Trade (DPIIT) towards a ` Viksit Bharat. This collaboration under DPIIT's Startup India initiative aims to build a stronger India by empowering its emerging biotech startups and providing access to work-of-art global technologies that deliver, foster, and promote the manufacturing ecosystem of the nation towards Viksit Bharat
29 <sup>th</sup> November	India's pharma market to double in size by 2030, hit \$120 billion, claims report Hindustan Times, November 29, 2024	<a href="#">India's pharma market to double in size by 2030, hit \$120 billion, claims report</a>	The Indian healthcare sector is on a trajectory of rapid growth, with the pharmaceutical market poised to double from its current valuation of USD60 billion to an estimated USD120 billion by 2030, according to a report by the Organisation of Pharmaceutical Producers of India (OPPI) in collaboration with the Boston Consulting Group (BCG).
29 <sup>th</sup> November	Indian pharma looking at \$4 bn opportunity in 3 yrs from patent expiries Deccan Herald, November 29, 2024	<a href="#">Indian pharma looking at \$4 bn opportunity in 3 yrs from patent expiries</a>	India's pharmaceutical market is poised to double, reaching \$120 billion by 2030 according to a report by Boston Consulting Group (BCG) and the Organisation of Pharmaceutical Producers of India (OPPI) out on Thursday.
29 <sup>th</sup> November	EY Parthenon - OPPI report claims India's pharma sector set for rapid growth Express Pharma, November 29, 2024	<a href="#">EY Parthenon - OPPI report claims India's pharma sector set for rapid growth</a>	EY Parthenon (EYP) in partnership with the Organisation of Pharmaceutical Producers of India (OPPI), released a report titled Viksit Bharat@2047: Transforming India from pharmacy of the world to pharma powerhouse for the world, to navigate the pharma industry's journey towards global excellence.

29 <sup>th</sup> November	Ahead of 2025 quality norms, Drug Controller asks pharma cos to Make in India CNBC TV18, November 29, 2024	<a href="#">Ahead of 2025 quality norms, Drug Controller asks pharma cos to Make in India</a>	Speaking at the annual summit of the Organization of Pharmaceutical Producers of India (OPPI), the DCGI said that the blood bank licensing system has been streamlined and digitized to save time and improve efficiency.
29 <sup>th</sup> November	India's Drug Regulator's Jibe: Pharma Lobby Should Be Called 'Importers' Not 'Producers' NDTV Profit, November 29, 2024	<a href="#">India's Drug Regulator's Jibe: Pharma Lobby Should Be Called 'Importers' Not 'Producers'</a>	It's high time for companies who are basically importing and marketing to invest in India and start manufacturing and doing research in India, so that the real contribution towards building Viksit Bharat comes from the companies who are capable of doing it," Central Drugs Standard Control Organisation Chief Dr. Rajeev Singh Raghuvanshi said at OPPI's Annual Summit.
29 <sup>th</sup> November	OPPI Annual Summit Presents the Roadmap on Becoming the Pharma Powerhouse to the World Business Standard, November 29, 2024	<a href="#">OPPI Annual Summit Presents the Roadmap on Becoming the Pharma Powerhouse to the World</a>	The Organisation of Pharmaceutical Producers of India (OPPI) organized its flagship Annual Summit today, at The Lalit, New Delhi. The summit brought together a distinguished assembly of key Government officials, regulators, industry leaders, member organisations, academia, patient support groups, innovators and other key stakeholders.
29 <sup>th</sup> November	Pharma leaders convene at OPPI Annual Summit 2024 to discuss India's path to global leadership The Financial Express, November 29, 2024	<a href="#">Pharma leaders convene at OPPI Annual Summit 2024 to discuss India's path to global leadership</a>	The Organisation of Pharmaceutical Producers of India (OPPI) organized its flagship Annual Summit on Thursday at The Lalit, New Delhi. The summit brought together a distinguished assembly of key Government officials, regulators, industry leaders, member organisations, academia, patient support groups, innovators and other key stakeholders.
29 <sup>th</sup> November	Pharma sector calls for incentives for innovation, R&D; pricing reforms, duty exemptions from govt CNBC TV18, November 29, 2024	<a href="#">Pharma sector calls for incentives for innovation, R&amp;D; pricing reforms, duty exemptions from govt</a>	Bhushan Akshikar, President of the Organization of Pharmaceutical Producers of India (OPPI) and Managing Director of GlaxoSmithKline Pharmaceuticals, stated that the industry is seeking pricing reforms and duty exemptions from the government.
29 <sup>th</sup> November	Govt likely to upgrade PLI scheme in the upcoming budget: Pharma Secy ET Pharma, November 29, 2024	<a href="#">Govt likely to upgrade PLI scheme in the upcoming budget: Pharma Secy</a>	Speaking at the OPPI annual summit, Dr Chawla said, "The scheme for strengthening the pharmaceutical industry is entering its last year and time has come to think of the post PLI framework... we will hope to do this over the next three months.
29 <sup>th</sup> November	Stricter GMP Norms: Revised Schedule M to Take Effect from New Year, says DCGI	<a href="#">Stricter GMP Norms: Revised Schedule M to Take Effect from New Year, says DCGI</a>	Speaking at the sidelines of an OPPI Annual Summit exclusively with ETPharma, Dr. Rajeev Raghuvanshi, Drug



	ET Pharma, November 29, 2024		Controller General of India (DCGI), highlighted the importance of Schedule M as a crucial part of the regulatory value chain.
29 <sup>th</sup> November	Johnson & Johnson India launches campaign to promote early lung cancer detection Express Healthcare, November 29, 2024	<a href="#">Johnson &amp; Johnson India launches campaign to promote early lung cancer detection</a>	Johnson & Johnson (J&J) India has introduced a nationwide campaign, India Detects to Defeat, aimed at emphasizing the importance of early detection and testing to improve lung cancer outcomes. As part of its first phase, the campaign features a collaboration with Amar Chitra Katha to create an illustrated booklet simplifying complex medical information.
29 <sup>th</sup> November	Merck Life Science Partners with DPIIT to Boost India's Biotech Startups Knn India, November 29, 2024	<a href="#">Merck Life Science Partners with DPIIT to Boost India's Biotech Startups</a>	In a significant push for India's biotech ecosystem, Merck Life Science has inked a Memorandum of Understanding (MoU) with the Department for Promotion of Industry and Internal Trade (DPIIT) under the Startup India initiative.

-----